AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Data from Theratope vaccine trial to be presented at breast cancer symposium.
2003 OCT 1 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM, BRA) announced that data from the final analysis of its Theratope vaccine phase III clinical trial in metastatic breast cancer will be presented at the 26th Annual San Antonio Breast Cancer Symposium (SABCS) being held at the Henry B. Gonzalez Convention Center in San Antonio, December 3-6, 2003.
David W. Miles, MD, BSc, FRCP, senior lecturer, and honorary consultant in medical oncology at Guy's Hospital in London, England and principal clinical investigator in the trial will present the results in an oral presentation.
Theratope is an investigational therapeutic cancer vaccine designed to stimulate an immune response to the tumor associated STn marker. Over 1500 patients have been enrolled in clinical trials of the vaccine. Phase I and II clinical trials have tested the vaccine in a number of cancer indications, including breast, ovarian, and colorectal cancers. The phase III trial involved 1030 women with metastatic breast cancer.
The company, and its collaborator Merck KGaA of Darmstadt, Germany, announced in June that the phase III trial of Theratope did not meet the two predetermined statistical endpoints of time to disease progression and overall survival. However, in one prestratified subset of over 300 women on hormonal treatment following chemotherapy, those on the Theratope arm appeared to show a favorable trend to improvement in survival. Further analyses of this subset are ...
- MERCK KGAA STARTS PHASE III STUDY OF STIMUVAX IN BREAST CANCER.
- News wire article from: AsiaPulse News June 22, 2009 700+ words
...MERCK-KGAA) Merck KGaA Initiates Phase III Study of Stimuvax in Breast Cancer Merck KGaA announces the launch...Stimuvax, in advanced breast cancer DARMSTADT, Germany...Jun. 22, 2009-- Merck KGaA, Darmstadt, Germany...
- Merck KGaA Initiates Phase III Study of Stimuvax in Breast Cancer.
- Press release article from: Business Wire June 22, 2009 700+ words
...in advanced breast cancer DARMSTADT, Germany -- Merck KGaA, Darmstadt...sponsored by Merck KGaA, which is...with advanced breast cancer at an estimated...In aDvanced brEast cancer (b)START...was done by Merck KGaA. References...
- Press Release: Metastatic breast cancer vaccine trial to continue, Biomira and...
- News wire article from: Asia Africa Intelligence Wire September 19, 2002 700+ words
...Biomira Inc and Merck KGaA would continue...with metastatic breast cancer. Theratope vaccine...of metastatic breast cancer. The Data Safety...the metastatic breast cancer indication...400 patients. Merck KgaA, of Darmstadt...
- Merck KGaA initiates Phase III study of Stimuvax in breast cancer.
- News wire article from: Chemical Business Newsbase June 22, 2009 700+ words
Merck KGaA, Darmstadt, Germany...advanced, inoperable breast cancer. The STRIDE study...recurrent or metastatic breast cancer. Overall survival...is sponsored by Merck KGaA, which is leading...patients with advanced breast cancer at an estimated...
- Merck KGaA suffers setback in clinical trials for breast cancer drug.
- News wire article from: Europe Intelligence Wire June 17, 2003 700+ words
...German pharmaceuticals specialist Merck KGaA and its Canadian partner Biomira announced their jointly developed breast cancer vaccine Theratope suffered important...vaccine for women with metastatic breast cancer. However, one group of patients...
- Merck KgaA, of Darmstadt, Germany, and Biomira Inc., of Edmonton, Alberta,...
- Newspaper article from: BioWorld International December 10, 2003 700+ words
* Merck KgaA, of Darmstadt, Germany, and Biomira...of Phase III data at the San Antonio Breast Cancer Symposium related to their study of...Theratope vaccine in women with metastatic breast cancer. Early this summer, the partners...
- BIOTECHNOLOGY BUSINESS NEWS: Biomira and Merck KgaA strike C$150 M deal.
- News wire article from: Chemical Business Newsbase June 15, 2001 700+ words
Biomira has signed a 15-year development and marketing deal with Merck KgaA to develop jointly vaccines for breast cancer (Theratrope) and lung cancer (BLP25) which work by boosting the body's immune system and...
- Biomira and Merck KGaA Announce Phase III Theratope(R) Vaccine Trial Does Not...
- Press release article from: PR Newswire June 17, 2003 700+ words
...TSX:BRA) and Merck KGaA of Darmstadt...with metastatic breast cancer did not meet the...III metastatic breast cancer study and determine...Pharmaceuticals Inc., Merck KGaA's wholly-owned...with metastatic breast cancer being treated with...disease. Biomira ...
- Merck KGaA returns Theratope rights to Biomira.
- Press release article from: PR Newswire June 7, 2004 700+ words
...Inc. (TSX:BRA) and Merck KGaA of Darmstadt, Germany...small cell lung cancer. Merck KGaA decided not to pursue...treatment of metastatic breast cancer, because additional...therefore, no longer meets Merck KGaA's commercial timetable...
- Merck, KGaA, returns Theratope rights.
- Newspaper article from: Cancer Weekly July 6, 2004 700+ words
...Inc., (BIOM) and Merck, KGaA, of Darmstadt, Germany...small cell lung cancer. Merck, KGaA, decided not to pursue...treatment of metastatic breast cancer, because additional...therefore, no longer meets Merck, KGaA's, commercial timetable...
Source: HighBeam Research, Data from Theratope vaccine trial to be presented at breast cancer...